Galmed Pharmaceuticals Ltd
GLMD
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.99M
Close$
$0.92
67.1% upside
Current Fair Value
67.1% upsideUndervalued by 67.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.99 Million |
|---|---|
| Enterprise Value | $1.39 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.39 |
| Beta | 0.74 |
| Outstanding Shares | 6,591,445 |
Return
| Return on Equity | -79.69% |
|---|---|
| Return on Assets | -69.35% |
| Return on Invested Capital | -66.60% |
Valuation & Multiples
| P/E Ratio | -0.27 |
|---|---|
| PEG | -0.37 |
| Price to Sales | - |
| Price to Book Ratio | 0.28 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.15 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 8, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Galmed Pharmaceuticals Ltd
CEO: Allen Baharaff Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is ...